Loading
A phase 1/2 trial of adebrelimab and decitabine in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, now recruiting.
Phase Ib/II Clinical Study of Adebrelimab in Combination With Decitabine, Albumin-bound Paclitaxel, and Gemcitabine for the First-line Treatment of Metastatic Pancreatic Cancer is a phase 1/2, interventional study registered as NCT06454448 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 20 participants, started 2024-06-15 and due to reach its primary completion in 2025-06. Interventions recorded: Adebrelimab;decitabine;. Conditions listed: Adebrelimab (SHR-1316); Decitabine; Metastatic Pancreatic Cancer. Primary outcome: Dose Limiting Toxicity (DLT); The recommended phase 2 dose (RP2D); Objective Response Rate (ORR). Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed diagnosis of pancreatic cancer (originating from the pancreatic ductal epithelium), with clinical records showing metastatic pancreatic cancer (stage IV according to the AJCC 8th edition TNM staging of pancreatic cancer); 3". Sites: China. No results are recorded here; the registry entry is the source.
Shares Adebrelimab, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Adebrelimab, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Adebrelimab, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Adebrelimab, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Adebrelimab, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Adebrelimab, Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Adebrelimab, Pancreatic cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Pancreatic cancer trials open today (registry snapshot and UK sites), Metastatic pancreatic ductal adenocarcinoma, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.